Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03422510 · ClinicalTrials.gov registry record · Phase 2
FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2 study, sponsored by Complexa.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT03422510 is a Phase 2 study that has completed, run by Complexa. The registered enrollment target is 33 participants.
The verdict
NCT03422510, a Phase 2 study, has completed, sponsored by Complexa.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is a multicenter, open label, randomized study investigating two dose titration regimens of CXA-10 in subjects at least 18 years of age with primary FSGS. The study will be performed at approximately 25 study centers across the United States of America (USA). The recruitment period is anticipated to be up to approximately 16 months. Approximately 30 subjects will be randomized to ensure 26 subjects complete the study. An optional 9 month open label is available
Interventions
- DRUG CXA-10
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2018-04-15 |
| Est. Completion | 2020-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03422510
The ClinicalTrials.gov registry entry for NCT03422510 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Complexa, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CXA-10 is the first listed.
NCT03422510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03422510 about?
NCT03422510 is a clinical study titled "FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)". This is a multicenter, open label, randomized study investigating two dose titration regimens of CXA-10 in subjects at least 18 years of age with primary FSGS. The study will be performed at approximately 25 study centers across the United States of America (USA). The recruitment period is anticipa...
What is the current status of trial NCT03422510?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2018-04-15. Estimated completion is 2020-07-31.
What interventions are being tested in trial NCT03422510?
The interventions under investigation include: CXA-10 (DRUG).
Who is sponsoring clinical trial NCT03422510?
This trial is sponsored by Complexa, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.